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A B S T R A C T
Background
Measles is an important cause of childhoodmorbidity andmortality globally, despite increasing vaccine coverage. Zinc plays a significant
role in the maintenance of normal immunological functions, therefore supplements given to zinc-deficient children will increase the
availability of zinc and could reduce measles-related morbidity and mortality. This is an update of a review first published in 2015.
Objectives
To assess the effects of zinc supplementation in reducing morbidity and mortality in children with measles.
Search methods
We searched CENTRAL (03 February 2017, Issue 2), MEDLINE (1946 to 03 February 2017), Embase (1974 to 03 February 2017),
CINAHL (1981 to 03 February 2017), LILACS (1982 to 03 February 2017), Web of Science (1985 to 03 February 2017), and
BIOSIS Previews (1985 to 27 June 2014). We also searched ClinicalTrials.gov, the Australian New Zealand Clinical Trials Registry
and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) on 03 February 2017 to identify
unpublished and ongoing studies.
Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs evaluating the effects of zinc in reducing morbidity and mortality in children
with measles.
Data collection and analysis
Two review authors independently assessed the studies for inclusion and extracted data on outcomes, details of the interventions, and
other study characteristics using a standardised data extraction form. We used risk ratio (RR) and hazard ratio (HR) as measures of
effect with 95% confidence intervals (CI). We included only one study, and did not conduct meta-analysis.
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Main results
We did not identify any new studies for inclusion in this update. One RCT met our inclusion criteria. The study was conducted in
India and included 85 children diagnosed with measles and pneumonia. The trial showed no significant difference in mortality between
children with measles and pneumonia who received zinc supplements and those who received placebo (RR 0.34, 95% CI 0.01 to 8.14).
There was no significant difference in time to absence of fever between children who received zinc supplements and those who did not
(HR 1.08, 95% CI 0.67 to 1.74). No treatment-related side effects were reported in either group. We assessed the overall quality of
the evidence as very low.
Authors’ conclusions
We could not draw any definitive conclusions from this review about the effects of zinc supplementation on clinical outcomes of
children with measles due to the very low quality of the evidence available. There is insufficient evidence to confirm or refute the effect
of zinc supplementation in children with measles.
P L A I N L A N G U A G E S U M M A R Y
Zinc supplementation for the treatment of measles in children
Review question
What is the effect of zinc supplementation in the treatment of children with measles?
Background
Measles infection has reduced globally over the last decade, but large outbreaks still occur, especially in low-income countries. Zinc is
one of the essential micronutrients necessary for the optimal functioning of the immune system. Zinc deficiency is particularly common
in children in low- and middle-income countries. It was therefore important to examine the potential role of zinc supplementation in
controlling the symptoms of measles infection in children.
We aimed to critically assess the current evidence from published studies on the effect of zinc supplementation for the treatment of
measles in children.
Search date
We searched for evidence up to 03 February 2017. This is an update of a review first published in 2015. We did not include any new
studies for this update.
Study characteristics
We found one small randomised trial (involving 85 children) that compared zinc supplements versus placebo administered to children
with measles and pneumonia. All 85 children received supportive care and vitamin A. The study was conducted in India and funded
by the Child Health Foundation USA and the Nestlé Foundation.
Key results
The included study was small and did not provide enough data to determine whether zinc had an effect on mortality when compared
with placebo. Although no adverse effects were reported, there was insufficient evidence to draw any conclusions about the use of zinc
supplements to improve measles symptoms in children. More research is needed to clarify any benefits or harms.
Quality of the evidence
We assessed the quality of the evidence as very low.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Zinc versus placebo for the treatment of measles in children
Patient or population: children with measles and pneumonia
Settings: tert iary care centre in a low-income country
Intervention: zinc
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Zinc
Mortality
Follow-up: mean 6 days
Study population RR 0.34
(0.01 to 8.14)
85
(1 study)
⊕⊕©©
very low1,2
23 per 1000 8 per 1000
(0 to 189)
Time to fever abate-
ment
Follow-up: mean 6 days
Study population HR 1.08
(0.67 to 1.74)
78
(1 study)
⊕⊕©©
very low1,2
Median t ime to absence
of fever 96 hours IQR
(74 to 116)
Median t ime to absence
of fever 96 hours IQR
(72 to 116)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; HR: hazard rat io; IQR: interquart ile range; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Serious imprecision: wide conf idence intervals, small sample size, and few events.
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2Indirectness: study populat ion dif fered clinically f rom children with uncomplicated measles.
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B A C K G R O U N D
Description of the condition
Measles is an important cause of childhoodmorbidity and mortal-
ity globally. It is a highly contagious acute viral infection charac-
terised by high fever, cough, rhinitis, conjunctivitis, a rash on the
mucous membranes, and a redmaculopapular rash (Mason 2016).
According to the World Health Organization, 535,000 children
died of measles in 2000 (WHO 2012). Between 2000 and 2010,
there was a 74% reduction in measles deaths globally as a result of
improved vaccine coverage efforts (Simons 2012). However, large
outbreaks occurred inBulgaria in 2009 to 2010 andFrance in 2011
as a result of suboptimal immunisation levels (Carrillo-Santisteve
2012). Measles outbreaks occurred in Sierra Leone (between 2009
and 2010) and South Africa (between 2003 and 2005; 2009 and
2011), likely due to HIV infection and poor vaccine coverage
(Sartorius 2013). Case fatality rates for measles among young chil-
dren in low-income countries still hover at around 5% to 6%
(Wolfson 2009). Acute lower respiratory infection is a common
complication of measles, and is associated with mortality. Other
important complications of measles include otitis media, laryn-
gotracheobronchitis (croup), diarrhoea, encephalitis, and cortical
damage leading to blindness (Perry 2004).
The global prevalence of zinc deficiency is estimated to be more
than 20% (Wuehler 2005), and in many low-income countries,
is extremely prevalent among children (World Bank 2016). Most
zinc is excreted through the gastrointestinal tract, therefore chil-
dren who are regularly exposed to gastrointestinal pathogens and
who have poor nutrition, low in animal products and high in phy-
tate, are most at risk of zinc deficiency (Lazzerini 2016). Zinc de-
ficiency results in the dysfunction of both humoral and cell-me-
diated immunity and increases susceptibility to infectious diseases
such as diarrhoea and respiratory infection (Tuerk 2009). Respi-
ratory tract infections, such as acute lower respiratory tract infec-
tions, are common complications of measles infection (Aggarwal
2007; Roth 2008; Shakur 2009).
Description of the intervention
Zinc is one of the most important trace elements in the human
body. It is a component of over 1000 transcription factors and is
required in more than 300 zinc-containing enzymes (Haase 2009;
Stefanidou 2006). Zinc supplementation may reduce the duration
of acute and persistent diarrhoea in children over six months of
age (Lazzerini 2016), and frequency of diarrhoeal and respiratory
illnesses in children (Aggarwal 2007). Zinc supplements can be
given in the forms of zinc sulphate, zinc gluconate, zinc acetate,
or zinc chloride. The recommended daily dose is 10 mg to 20 mg
of zinc for children with diarrhoea (WHO/UNICEF 2004).
How the intervention might work
Several studies have demonstrated the importance of zinc in the
maintenance of normal immune functions (Bach 1989; Prasad
1998; Prasad 2000; Prasad 2009; Stefanidou 2006; Tapiero 2003).
Zinc is said to be crucial for effective innate and acquired immu-
nity, and insufficient zinc status could be the most common cause
of secondary immunodeficiency in humans (Tapiero 2003). Zinc
deficiency impairs phagocytosis of macrophages and neutrophils,
oxidative burst activity, and complement natural killer cell activity
(Prasad 2000). Zinc is also involved in T-cell differentiation and
enhancement of T-cell and natural killer cell actions through its
role in thymulin activity (Bach 1989). In the absence of zinc, lym-
phocyte proliferation is depressed, as well as delayed-type hyper-
sensitivity skin responses and T-cell dependent antigen-antibody
responses (Prasad 1998). Zinc has also been shown to have anti-in-
flammatory and antioxidant properties (Prasad 2009; Stefanidou
2006). Supplements increase the availability of zinc for these im-
munologic processes and may improve measles morbidity and
mortality. In children, zinc supplementation is reported to reduce
morbidity, mortality, and recovery time from acute infectious dis-
eases (Cuevas 2005). Sazawal 2007 showed that zinc supplements
given to children aged between 1 month and 48 months resulted
in reducedmortality from acute infections includingmeasles. Zinc
supplementation has also been shown to significantly reduce res-
piratory morbidity in preschool children (Sazawal 1998), and may
reduce the incidence of acute lower respiratory tract infections by
improving measles morbidity.
Why it is important to do this review
Several reviews have shown that zinc supplementation is associated
with reduced incidence and prevalence of pneumonia in children
(Aggarwal 2007; Bhutta 1999; Lassi 2016). Other Cochrane Re-
views evaluating zinc supplementation in children have looked at
otitis media and diarrhoea (Gulani 2014; Lazzerini 2016). This
review aimed to identify, critically appraise, and synthesise data
from studies evaluating the effects of zinc supplementation in chil-
dren with measles.
O B J E C T I V E S
To assess the effects of zinc supplementation in reducingmorbidity
and mortality in children with measles.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs evaluating
the effects of zinc in reducing morbidity and mortality in children
with measles.
Types of participants
Children aged up to 18 years diagnosed with measles.
Types of interventions
Zinc supplementation (irrespective of dosage, duration, and route
of administration) combined with standard treatment compared
with standard treatment alone or standard treatment with placebo.
(Standard treatment was defined as relief of common symptoms
such as fever, cough, blocked nose, conjunctivitis, and sore mouth;
provision of nutritional support; and vitamin A (WHO 2004).)
Types of outcome measures
Primary outcomes
1. All-cause mortality.
Secondary outcomes
1. Duration of fever, coryza, cough, and rash.
2. Duration of hospitalisation.
3. Incidence of complications such as pneumonia, otitis
media, diarrhoea, and croup.
4. Effect on disability-adjusted life years.
5. Adverse events.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (03 February 2017, Issue 2), which contains the
Cochrane Acute Respiratory Infections Group Specialised Reg-
ister, MEDLINE (1946 to 03 February 2017), Embase (1974
to 03 February 2017), CINAHL (Cumulative Index to Nurs-
ing and Allied Health Literature) (1981 to 03 February 2017),
LILACS (Latin American and Caribbean Health Science Litera-
ture Database) (1982 to 03 February 2017), Web of Science (1985
to 03 February 2017), and BIOSIS Previews (1985 to 27 June
2014). We did not update the BIOSIS Previews search in February
2017 due to lack of institutional access to that database.
We used the search strategy described in Appendix 1 to search
CENTRALandMEDLINE.We combined theMEDLINEsearch
with the Cochrane Highly Sensitive Search Strategy for identify-
ing randomised trials in MEDLINE: sensitivity- and precision-
maximising version (2008 revision);Ovid format (Lefebvre 2011).
We adapted the search strategy to search Embase (Appendix 2),
CINAHL (Appendix 3), LILACS (Appendix 4), Web of Science
(Appendix 5), and BIOSIS Previews (Appendix 6). We did not
apply any language or publication restrictions.
Searching other resources
We searched ClinicalTrials.gov, the Australian New Zealand Clin-
ical Trials Registry and the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP) for un-
published and ongoing studies (latest search 03 February 2017).
We scrutinised the reference lists of the included studies and rele-
vant review articles for additional references.
Data collection and analysis
Selection of studies
Two review authors (AA, OO) independently screened the titles
and abstracts of articles identified by the searches for eligibility.We
classified these studies as ’included’ or ’excluded’.We retrieved full-
text articles of studies that did not have an abstract or had a limited
abstract and assessed them for inclusion. Two review authors (AA,
OO) independently assessed full-text articles classified as ’include’
for inclusion in the review using a standardised form with explicit
inclusion and exclusion criteria. Any disagreements were resolved
by the two review authors. Only one study met our inclusion
criteria.
Data extraction and management
Two review authors (AA, AS) independently extracted data from
the included studies using a pre-designed data extraction form.
We extracted the following information:
• general information (study ID, date of extraction, title,
authors, and source of study if not published);
• study characteristics (study design, participants, and
inclusion/exclusion criteria used in the study);
• details of the interventions (including zinc dosage,
treatment duration, comparison details, duration of follow-up);
• outcomes as described in Types of outcome measures above;
and
• details necessary for ’Risk of bias’ assessment.
We resolved disagreements by discussion.
Assessment of risk of bias in included studies
We identified no new studies in this update. For the 2015 ver-
sion of this review, we used the ’Risk of bias’ assessment tool and
criteria set out in the Cochrane Handbook for Systematic Reviews
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of Interventions to assess the risk of bias for the included study
(Higgins 2011). Two review authors (AA, AS) independently as-
sessed the risk of bias of the included study by assessing randomi-
sation sequence generation; allocation concealment; blinding of
participants, personnel, and outcome assessors; incomplete out-
come data; selective outcome reporting; and other sources of bias.
We resolved disagreements through discussion. We reported re-
sults in a ’Risk of bias’ table.
Measures of treatment effect
We presented results for dichotomous outcomes as risk ratio (RR)
and hazard ratio (HR) with 95% confidence intervals (CI) (as
reported in the included study). For continuous outcomes, we
intended to express the measure of effect as a mean difference
(MD) with 95% CI. However, data from the included study did
not permit this analysis.
Dealing with missing data
We found attrition rates of 9.52% in the zinc arm and 11.62% in
the placebo arm of the included study.We did not impute missing
data.
Assessment of heterogeneity
We planned to assess statistical heterogeneity via visual inspection
of forest plots of the included trials, using the Chi² test and the I²
statistic, where data from included trials could be pooled. How-
ever, as there was only one included study, we could not conduct
this assessment using the available data.
Assessment of reporting biases
We compared the list of outcomes in the methods section of the
included study to the outcomes reported. We could not create an
inverted funnel plot to check for possible publication bias because
there were too few included studies.
Data synthesis
We entered data into ReviewManager 5 software (RevMan 2014).
As only one study was included in this review, data could not be
combined for meta-analysis. We provided a narrative summary of
findings for the included study.
GRADE and ’Summary of findings’ table
We created a Summary of findings for the main comparison us-
ing the following outcomes: mortality and time to fever abate-
ment.We used the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness, and publication
bias) to assess the quality of evidence as it related to the included
study (Atkins 2004). We used methods and recommendations de-
scribed in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), employing
GRADEpro GDT software (GRADEpro GDT 2014). We justi-
fied decisions to downgrade study quality in footnotes, and made
comments to aid readers understanding of the review where nec-
essary.
Subgroup analysis and investigation of heterogeneity
We planned to explore any observed significant heterogeneity by
conducting subgroup analyses based on the characteristics of par-
ticipants (inpatient and outpatient, age group), type of compari-
son (placebo and standard treatment), type of supplement, dose
and duration of supplement, and immunisation status. Due to
insufficent data we were unable to conduct these analyses.
Sensitivity analysis
We planned to conduct sensitivity analyses to assess the impact of
high risk of bias on meta-analysed outcomes by gradually adding
studies with high risk of bias to pooled studies with low risk of
bias. We did not perform these analyses due to insufficient data.
R E S U L T S
Description of studies
Results of the search
This is an update of a review first published in 2015. The most
recent search (February 2017) did not identify any new studies for
inclusion (Figure 1; Characteristics of included studies).
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Figure 1. Study flow diagram.
We retrieved 48 records from the searches of electronic databases.
We found no ongoing studies in the following trial registries: Clin-
icalTrials.gov, the AustralianNew Zealand Clinical Trials Registry,
and the WHO ICTRP. Two review authors (AA, OO) indepen-
dently scanned titles and abstracts using prespecified inclusion cri-
teria. We identified four potentially eligible studies and obtained
full-text articles. One study met our inclusion criteria and was in-
cluded in the review. We provided reasons for excluding a poten-
tially eligible study (see Characteristics of excluded studies).
Included studies
We included one RCT (three reports) that compared zinc supple-
ment with placebo (Mahalanabis 2002). This was a double-blind,
randomised, placebo-controlled trial carried out in a tertiary care
hospital in India. There were 85 participants: 42 in the zinc group
and 43 in the placebo group. Participants were children admitted
to the hospital with an illness that was compatible with measles
(generalised maculopapular rash with fever and at least one of the
following: cough, coryza, or conjunctivitis and a clinical diagnosis
of acute lower respiratory tract infection (pneumonia)). Children
who had congenital anomalies, chronic diseases, or severe malnu-
trition were excluded from the study.
Mahalanabis 2002 compared a zinc acetate mixture containing
20 mg elemental zinc with placebo, each given twice daily for six
days. All trial participants also received a single dose of vitamin
A and antibiotics. The duration of therapy and follow-up was six
days. The study aimed to compare the clinical status (duration
of significant illness, fever and tachypnoea) of participants in the
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zinc and placebo groups. The study also assessed serum zinc and
retinol concentrations. Mahalanabis 2002 used the Chi² test or
Fisher’s exact test as well as survival analysis (Cox proportional
hazards model) to compare groups. P values were reported.
The baseline characteristics of children in the zinc and placebo
groups were similar. These included age, gender, duration of
measles rash, weight-for-age (z score), height-for-age (z score), and
difficulty in eating or feeding (%). Five participants in the placebo
arm and three in the zinc arm withdrew from the study; one child
in the zinc arm dropped out on day one due to breakage of the
bottle containing the supplement. One child in the control group,
who was admitted in a coma and diagnosed clinically with septi-
caemia, died.
Excluded studies
We excluded one study: Tielsch 2007 included children who did
not have measles (see Characteristics of excluded studies).
Risk of bias in included studies
We assessed risk of bias in the included study using the Cochrane
’Risk of bias’ tool for RCTs (Figure 2). We assessed risk of bias as
low for most domains, and unclear for selective reporting.
Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Allocation of participants to receive either the zinc supplement or
placebo was done using permuted blocks of random numbers to
create a master randomisation schedule. The allocation sequence
was concealed using serially numbered, identical bottles. We as-
sessed Mahalanabis 2002 as at low risk of bias for this domain.
Blinding
Participants received serially numbered bottles, which contained
mixtures that were identical in colour, consistency, and taste, en-
suring adequate blinding. We assessedMahalanabis 2002 as at low
risk of bias for this domain.
Incomplete outcome data
Losses to follow-up were similar in both the intervention and
control groups. The attrition rates were 9.52% in the zinc group
and 11.62% in the placebo group. We assessed Mahalanabis 2002
as at low risk of bias for this domain.
Selective reporting
We could not locate a registered trial protocol to compare the pre-
specified outcomes with the outcomes reported in themanuscript.
We assessed Mahalanabis 2002 as at unclear risk of bias for this
domain.
Other potential sources of bias
We did not identify any other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Zinc versus
placebo for the treatment of measles in children
Mahalanabis 2002 reported the following outcomes: median
(quartiles) time required for resolution of fever and tachypnoea,
return of appetite, and achievement of a much improved or cured
status. This review proposed assessment of a number of other out-
comes that were not reported by Mahalanabis 2002: duration of
coryza, cough, and rash; incidence of complications such as pneu-
monia, otitis media, diarrhoea, and croup; and effect on disability-
adjusted life years.
Primary outcome
1. All-cause mortality
There was no statistically significant difference in all-cause mor-
tality between children in the zinc supplementation plus standard
treatment group and children in the placebo plus standard treat-
ment group (RR 0.34, 95% CI 0.01 to 8.14; P = 0.51; Analysis
1.1; Figure 3).
Figure 3. Forest plot of comparison: 1 Zinc versus placebo, outcome: 1.1 Mortality.
Secondary outcomes
1. Duration of fever, coryza, cough, and exanthema (rash)
Zinc supplementation in children with measles showed a non-
significant effect on time to absence of fever compared to the
placebo group (HR 1.08, 95%CI 0.67 to 1.74, fixed-effectmodel;
P = 0.75; Analysis 1.2; Figure 4).
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Figure 4. Forest plot of comparison: 1 Zinc versus placebo, outcome: 1.2 Time to fever abatement.
2. Duration of hospitalisation
All children enrolled were hospitalised for the study duration (
Mahalanabis 2002).
3. Incidence of complications such as pneumonia, otitis
media, diarrhoea, and croup
Mahalanabis 2002 did not report the incidence of complications.
4. Effect on disability-adjusted life years
Mahalanabis 2002 did not report the effect on disability-adjusted
life years.
5. Adverse events
Mahalanabis 2002 did not report any treatment-related side effects
in either group.
D I S C U S S I O N
Summary of main results
This is an update of a review first published in 2015 and included
no new studies. Previous conclusions are unchanged.
The included study involved 85 children: 42 received a zinc acetate
mixture containing 20 mg elemental zinc, and 43 received placebo
(Mahalanabis 2002). All childrenwere diagnosedwithmeasles and
pneumonia and all received vitamin A and antibiotics. One child
in the placebo group died during the trial.
Mahalanabis 2002 demonstrated no significant difference in du-
ration of fever between groups. All enrolled children were hospi-
talised for the entire duration of the study. No treatment-related
side effects were reported in either group.
Overall completeness and applicability of
evidence
We conducted a comprehensive search to identify all relevant
studies that met our inclusion criteria. We found only one study
that met the inclusion criteria. There was no significant differ-
ence in outcomes reported between groups in the included study
(Mahalanabis 2002).
The evidence for this review was drawn from a single small study
that was not adequately powered. Mahalanabis 2002 was con-
ducted in a tertiary healthcare setting in India. We are not confi-
dent about the observed effect estimates because of imprecision of
the results. It is therefore difficult to comment on the applicability
of the available evidence.
Quality of the evidence
We used the GRADE approach to assess the quality of the ev-
idence in this review (GRADEpro GDT 2014; Higgins 2011;
Schünemann 2011). We carried out one comparison: zinc acetate
versus placebo for children with measles for two outcomes (mor-
tality and reduction of fever duration). We downgraded the qual-
ity of the evidence based on imprecision of the effect estimates
(small sample size and few events) and indirectness. We assessed
the quality of the evidence as very low. We are therefore very un-
certain about the estimate.
Potential biases in the review process
We identified one RCT for inclusion using the comprehensive
search strategy developed by the Cochrane Acute Respiratory In-
fections Group. We applied no language or publication limita-
tions. We also searched three clinical trial registries and did not
find any ongoing trials. Other potential biases were limited by en-
suring that two review authors independently conducted the study
selection, quality assessment, and data extraction.
Agreements and disagreements with other
studies or reviews
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A previous Cochrane Review did not find sufficient evidence to
support use of zinc as an adjunct to standard antibiotic therapy
for pneumonia in children aged 2 months to 35 months (Haider
2011). Another Cochrane Review concluded that zinc supplemen-
tation in children is associated with a reduction in the incidence
and prevalence of pneumonia (Lassi 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We could draw no definitive conclusions from this review about
the effects of zinc supplementation on clinical outcomes for chil-
dren with measles due to the very low quality of the available ev-
idence. The current evidence is not conclusive and neither sup-
ports nor refutes the use of zinc supplementation in children with
measles.
Implications for research
Adequately powered studies addressing clinically relevant out-
comes such as age-specific mortality, incidence of complications
(such as pneumonia, otitis media, diarrhoea, and croup), and the
effect on disability-adjusted life years are required for better as-
sessment of the impact of zinc supplementation in children with
measles.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Mahalanabis 2002
Methods Study design: randomised, placebo-controlled trial
Study duration: 6 days (dates not reported)
Participants Inclusion criteria
• Setting: tertiary care hospital
• Country: India
• Health status: children admitted to the hospital with an illness that was
compatible with measles and a clinical diagnosis of acute lower respiratory infection
(pneumonia)
• Number: zinc + supportive care (N = 42); placebo + supportive care (N = 43)
• Age: 9 months to 15 years
• Sex (M/F): zinc group (18/24); placebo (25/18)
Exclusion criteria
• Congenital anomalies
• Chronic diseases
• Severe malnutrition
Interventions Zinc group
• Zinc acetate mixture containing 20 mg elemental zinc given twice daily for 6 days
• Vitamin A and antibiotics
Placebo group
• Syrup-based mixture given twice daily for 6 days
• Vitamin A and antibiotics
Outcomes The main outcome of the study was the clinical status of the participants. Serum zinc
and retinol concentrations were also assessed
Notes The study protocol was approved by the hospital’s ethics committee
Funding: The study was funded by the Child Health Foundation (USA) and the Nestlé
Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted blocks of random numbers to
create a master randomisation schedule
Allocation concealment (selection bias) Low risk Serially numbered, identical bottles
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Serially numbered bottles that contained
mixtures that were identical in colour,
consistency, and taste, ensuring adequate
blinding
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Mahalanabis 2002 (Continued)
An independent pharmaceutical chemist
ensured adequate blinding of the primary
investigators
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The evaluating physician had no knowl-
edge of the treatment group to which any
of the children belonged
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were 9.52% in the zinc
group and 11.62% in the placebo group
Selective reporting (reporting bias) Unclear risk No protocol with prespecified outcomes
identified.
Other bias Low risk None
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Tielsch 2007 This was a community-based, cluster-randomised, double-masked, placebo-controlled 2 x 2 factorial trial in children
aged 1 to 35 months. The study participants did not have measles
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D A T A A N D A N A L Y S E S
Comparison 1. Zinc versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.01, 8.14]
2 Time to fever abatement 1 78 Hazard Ratio (Fixed, 95% CI) 1.08 [0.67, 1.74]
Analysis 1.1. Comparison 1 Zinc versus placebo, Outcome 1 Mortality.
Review: Zinc supplementation for the treatment of measles in children
Comparison: 1 Zinc versus placebo
Outcome: 1 Mortality
Study or subgroup Zinc Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mahalanabis 2002 0/42 1/43 100.0 % 0.34 [ 0.01, 8.14 ]
Total (95% CI) 42 43 100.0 % 0.34 [ 0.01, 8.14 ]
Total events: 0 (Zinc), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours zinc Favours placebo
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Analysis 1.2. Comparison 1 Zinc versus placebo, Outcome 2 Time to fever abatement.
Review: Zinc supplementation for the treatment of measles in children
Comparison: 1 Zinc versus placebo
Outcome: 2 Time to fever abatement
Study or subgroup Zinc Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Mahalanabis 2002 40 38 0.07696 (0.24346) 100.0 % 1.08 [ 0.67, 1.74 ]
Total (95% CI) 40 38 100.0 % 1.08 [ 0.67, 1.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours zinc Favours placebo
A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy
1 exp Measles/
2 exp Measles virus/
3 Morbillivirus Infections/
4 Morbillivirus/
5 (measles* or rubeola*).tw.
6 or/1-5
7 exp Zinc/
8 exp Zinc Acetate/
9 Zinc Sulfate/
10 exp Zinc Compounds/
11 (zinc or zn).tw,nm.
12 Trace Elements/
13 Dietary Supplements/
14 or/7-13
15 6 and 14
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Appendix 2. Embase (Elsevier) search strategy
#1
#1.14 #1.5 AND #1.13 87
#1.13 #1.6 OR #1.7 OR #1.8 OR #1.9 OR #1.10 OR #1.11 OR #1.12
#1.12 zinc:ab,ti OR zn:ab,ti AND [embase]/lim
#1.11 ’zinc derivative’/de AND [embase]/lim
#1.10 ’zinc chloride’/de AND [embase]/lim
#1.9 ’gluconate zinc’/de AND [embase]/lim
#1.8 ’zinc sulfate’/de AND [embase]/lim
#1.7 ’zinc acetate’/de AND [embase]/lim
#1.6 ’zinc’/de AND [embase]/lim
#1.5 #1.1 OR #1.2 OR #1.3 OR #1.4
#1.4 measles:ab,ti OR rubeola:ab,ti AND [embase]/lim
#1.3 ’morbillivirus infection’/de AND [embase]/lim
#1.2 ’measles virus’/de AND [embase]/lim
#1.1 ’measles’/de AND [embase]/lim
#2
#2.8 #2.3 NOT #2.7 881901
#2.7 #2.4 NOT #2.6
#2.6 #2.4 AND #2.5
#2.5 ’human’/de AND [embase]/lim
#2.4 ’animal’/de OR ’nonhuman’/de OR ’animal experi-
ment’/de AND [embase]/lim
#2.3 #2.1 OR #2.2
#2.2 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti
OR ’cross over’:ab,tiOR allocat*:ab,tiOR trial:tiOR (doubl*
NEXT/1 blind*):ab,ti AND [embase]/lim
#2.1 ’randomized controlled trial’/expOR ’single blind pro-
cedure’/exp OR ’double blind procedure’/exp OR ’crossover
procedure’/exp AND [embase]/lim
#3 #1 AND #2
Appendix 3. CINAHL (Ebsco) search strategy
S1 (MH “Measles+”)
S2 TI (measles or rubeola) OR AB (measles or rubeola)
S3 S1 OR S2
S4 (MH “Zinc”)
S5 (MH “Zinc Compounds+”)
S6 (MH “Trace Elements”)
S7 (MH “Dietary Supplements”)
S8 TI (zinc or zn) OR AB (zinc or zn)
S9 S4 OR S5 OR S6 OR S7 OR S8
S10 S3 AND S9
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Appendix 4. LILACS (BIREME) search strategy
w:((mh:measles OR measles OR sarampión OR sarampo OR rubeola OR mh:c02.782.580.600.500.500* OR mh:“Measles virus”
OR mh:b04.820.455.600.650.500.500* OR mh:b04.909.777.455.600.650.500.500* OR mh:“Morbillivirus Infections” OR mh:
morbillivirus) AND (mh:zinc OR zinc OR zinco OR mh:“Zinc Compounds” OR mh:d01.975* OR mh:“Zinc Acetate” OR zn OR
mh:“Trace Elements” OR mh:“Dietary Supplements”)) AND (instance:“regional”) AND ( type˙of˙study:(“clinical˙trials”))
Appendix 5. Web of Science (Thomas Reuters) search strategy
#1 TOPIC: (measles or rubeola)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
#2 TOPIC: (zinc or zn)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
#3 #2 AND #1
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
#4 TOPIC: (random* or placebo* or crossover* or “cross over” or allocat* or ((singl* or doubl*) NEAR/1 blind*)) OR TITLE:
(trial)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
#5 #4 AND #3
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC Timespan=All years
Appendix 6. BIOSIS Previews (Thomson Reuters) search strategy
#1 TOPIC: (measles or rubeola)
Indexes=BIOSIS Previews Timespan=All years
#2 TOPIC: (zinc or zn)
Indexes=BIOSIS Previews Timespan=All years
#3 #2 AND #1
Indexes=BIOSIS Previews Timespan=All years
#4 TOPIC: (random* or placebo* or crossover* or “cross over” or allocat* or ((singl* or doubl*) NEAR/1 blind*)) OR TITLE:
(trial)
Indexes=BIOSIS Previews Timespan=All years
#5 #4 AND #3
Indexes=BIOSIS Previews Timespan=All years
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WH A T ’ S N E W
Last assessed as up-to-date: 3 February 2017.
Date Event Description
3 February 2017 New citation required but conclusions have not changed Our conclusions remain unchanged.
3 February 2017 New search has been performed We did not identify any new trials for inclusion.
C O N T R I B U T I O N S O F A U T H O R S
Ajibola Awotiwon wrote the protocol, with insightful comments from Olabisi Oduwole, Anju Sinha, and Charles Okwundu.
Ajibola Awotiwon and Olabisi Oduwole reviewed the search outputs, selected studies for inclusion, and located copies of relevant
studies.
Ajibola Awotiwon and Anju Sinha extracted data.
Ajibola Awotiwon wrote the review under the supervision of Charles Okwundu.
Ajibola Awotiwon, Olabisi Oduwole, and Anju Sinha reviewed the updated search results.
Ajibola Awotiwon updated the review.
D E C L A R A T I O N S O F I N T E R E S T
Ajibola Awotiwon: none known.
Olabisi Oduwole: none known.
Anju Sinha: none known.
Charles Okwundu: none known.
S O U R C E S O F S U P P O R T
Internal sources
• Center for Evidence-based Health Care, Stellenbosch University, South Africa.
21Zinc supplementation for the treatment of measles in children (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Fever [therapy]; Measles [complications; mortality; ∗therapy]; Pneumonia [therapy]; Randomized Controlled Trials as Topic; Zinc
[∗administration & dosage; deficiency]
MeSH check words
Child; Humans
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